# Feasible Analyses Summary
## What Can Be Done With Available Data

### ✅ COMPLETED & IN PROGRESS

1. **Visualization Generation** - ✅ IN PROGRESS
   - 15 ultra HD visualizations being generated
   - All analyses visualized comprehensively

2. **SHAP Interpretation** - ✅ FEASIBLE
   - Model trained and ready
   - SHAP library integrated
   - Can generate SHAP plots and interpretations
   - **Status**: Will run after visualizations complete

3. **Subgroup Analysis** - ✅ FEASIBLE
   - Clinical metadata available (60 samples)
   - Can stratify by: Group (Ruptured/Unruptured), Sex/Gender, Age
   - **Status**: Will run after visualizations complete

4. **Biomarker Panel Optimization** - ✅ FEASIBLE
   - Expression data available (39,376 genes, 60 samples)
   - DE analysis complete (top genes identified)
   - Can test panel sizes 5, 10, 15, 20, 25, 30 genes
   - **Status**: Will run after visualizations complete

5. **Drug Target Identification** - ✅ FEASIBLE
   - Prioritized genes available
   - Can map to druggable gene families
   - **Status**: Will run after visualizations complete

6. **PHASES Score Comparison** - ⚠️ PARTIALLY FEASIBLE
   - Clinical data available but incomplete PHASES components
   - Can create framework for comparison
   - **Status**: Framework will be created

### ❌ NOT FEASIBLE WITH CURRENT DATA

1. **Longitudinal Analysis** - ❌ NOT FEASIBLE
   - **Reason**: No time series data
   - **Required**: Serial measurements over time
   - **Status**: Cannot proceed

2. **Single-Cell RNA-seq Integration** - ❌ NOT FEASIBLE
   - **Reason**: GSE122897 is bulk RNA-seq, not single-cell
   - **Required**: Single-cell data (GSE186927 was incorrect dataset)
   - **Status**: Cannot proceed

3. **Exosomal Biomarker Discovery** - ❌ NOT FEASIBLE
   - **Reason**: No exosome sequencing data
   - **Required**: Exosome RNA-seq data
   - **Status**: Cannot proceed

4. **Imaging Data Integration** - ❌ NOT FEASIBLE
   - **Reason**: No imaging data (MRI, CTA, DSA)
   - **Required**: Imaging features (size, shape, wall enhancement)
   - **Status**: Cannot proceed

5. **Proteomics Integration** - ❌ NOT FEASIBLE
   - **Reason**: No proteomics data
   - **Required**: Protein expression data (mass spec, Olink, etc.)
   - **Status**: Cannot proceed

6. **Metabolomics Integration** - ❌ NOT FEASIBLE
   - **Reason**: No metabolomics data
   - **Required**: Metabolite data (LC-MS, GC-MS)
   - **Status**: Cannot proceed

7. **Epigenomics Analysis** - ❌ NOT FEASIBLE
   - **Reason**: No DNA methylation data
   - **Required**: Methylation arrays or WGBS data
   - **Status**: Cannot proceed

8. **Microbiome Analysis** - ❌ NOT FEASIBLE
   - **Reason**: No microbiome data
   - **Required**: 16S rRNA or metagenomic sequencing
   - **Status**: Cannot proceed

---

## Current Progress

### Running Now:
- ✅ Visualization generation (15 figures)
- ✅ SHAP interpretation
- ✅ Subgroup analysis
- ✅ Biomarker panel optimization
- ✅ Drug target identification
- ✅ PHASES comparison framework

### Expected Outputs:

**Visualizations (results/figures/ultra_hd/):**
1. volcano_plot_ultra_hd.png
2. ma_plot_ultra_hd.png
3. top_genes_heatmap_ultra_hd.png
4. model_performance_ultra_hd.png
5. feature_importance_ultra_hd.png
6. risk_stratification_ultra_hd.png
7. pathway_enrichment_ultra_hd.png
8. blood_signature_ultra_hd.png
9. ec_dysfunction_ultra_hd.png
10. integration_summary_dashboard_ultra_hd.png
11. gene_prioritization_ultra_hd.png
12. model_comparison_ultra_hd.png
13. feature_distributions_ultra_hd.png
14. roc_curve_ultra_hd.png
15. master_comprehensive_figure_ultra_hd.png
16. shap_summary_plot_ultra_hd.png
17. shap_bar_plot_ultra_hd.png
18. shap_waterfall_sample_*_ultra_hd.png (multiple samples)

**Analysis Results (results/analysis/):**
1. shap_feature_importance.tsv - SHAP values
2. subgroup_analysis.tsv - Subgroup performance
3. biomarker_panel_optimization.tsv - Panel size optimization
4. drug_targets_identified.tsv - Druggable targets
5. phases_comparison_framework.json - PHASES comparison framework

---

## Next Steps After Script Completes

1. Review generated visualizations
2. Examine SHAP interpretation results
3. Analyze subgroup differences
4. Select optimal biomarker panel
5. Prioritize drug targets for validation
6. Document limitations (missing data types)
7. Prepare manuscript materials

---

**Last Updated**: During script execution
**Status**: 6/14 analyses feasible with current data

